WO2025100417A1 - Aavのフルカプシドに対するアフィニティポリペプチド - Google Patents

Aavのフルカプシドに対するアフィニティポリペプチド Download PDF

Info

Publication number
WO2025100417A1
WO2025100417A1 PCT/JP2024/039335 JP2024039335W WO2025100417A1 WO 2025100417 A1 WO2025100417 A1 WO 2025100417A1 JP 2024039335 W JP2024039335 W JP 2024039335W WO 2025100417 A1 WO2025100417 A1 WO 2025100417A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
amino acid
acid sequence
positions
aav
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/JP2024/039335
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
裕道 大倉
由紀 平林
陽一 熊田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daicel Corp
Kyoto Institute of Technology
Original Assignee
Daicel Corp
Kyoto Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daicel Corp, Kyoto Institute of Technology filed Critical Daicel Corp
Priority to JP2025556404A priority Critical patent/JPWO2025100417A1/ja
Priority to CN202480069293.0A priority patent/CN122122177A/zh
Publication of WO2025100417A1 publication Critical patent/WO2025100417A1/ja
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material

Definitions

  • the present disclosure relates to affinity polypeptides for the full capsid of adeno-associated virus (AAV).
  • AAV adeno-associated virus
  • AAV adeno-associated virus
  • Patent Document 1 Specific methods for quantifying full capsids include quantitative PCR (Patent Document 1) and coherent scattering mass spectrometry (Patent Document 2).
  • affinity molecules suitable for quantifying full capsids should have higher binding affinity to AAV full capsids than to empty AAV capsids (i.e., selective binding to AAV full capsids).
  • the present disclosure therefore aims to provide an affinity molecule that has higher binding affinity to AAV full capsids than to empty AAV capsids.
  • Item 1 An anti-AAV full capsid molecule, which is an antibody having a higher binding affinity to an AAV full capsid than to an AAV empty capsid.
  • Item 2. A heavy chain variable region comprising, as heavy chain complementarity determining regions, CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 1, CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 2, and CDR3 consisting of an amino acid sequence having 90% or more sequence identity with the amino acid sequence represented by SEQ ID NO: 3;
  • An anti-AAV full capsid molecule comprising a light chain variable region including, as light chain complementarity determining regions, CDR1 consisting of the amino acid sequence represented by SEQ ID NO:4, CDR2 consisting of RAS, and CDR3 consisting of an amino acid sequence having 90% or more sequence identity with the amino acid sequence represented by SEQ ID NO:5.
  • a heavy chain variable region comprising, as heavy chain complementarity determining regions, CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 6, CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 7, and CDR3 consisting of an amino acid sequence having 90% or more sequence identity with the amino acid sequence represented by SEQ ID NO: 8;
  • An anti-AAV full capsid molecule comprising a light chain variable region including, as light chain complementarity determining regions, CDR1 consisting of the amino acid sequence represented by SEQ ID NO:9, CDR2 consisting of RAS, and CDR3 consisting of an amino acid sequence having 90% or more sequence identity with the amino acid sequence represented by SEQ ID NO:10.
  • a heavy chain variable region comprising, as heavy chain complementarity determining regions, CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 11, CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 12, and CDR3 consisting of an amino acid sequence having 90% or more sequence identity with the amino acid sequence represented by SEQ ID NO: 13;
  • An anti-AAV full capsid molecule comprising a light chain variable region including, as light chain complementarity determining regions, CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 14, CDR2 consisting of QAS, and CDR3 consisting of an amino acid sequence having 90% or more sequence identity with the amino acid sequence represented by SEQ ID NO: 15. Item 5.
  • a heavy chain variable region comprising, as heavy chain complementarity determining regions, CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 16, CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 17, and CDR3 consisting of an amino acid sequence having 90% or more sequence identity with the amino acid sequence represented by SEQ ID NO: 18;
  • An anti-AAV full capsid molecule comprising a light chain variable region including, as light chain complementarity determining regions, CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 19, CDR2 consisting of RAS, and CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 20.
  • the heavy chain variable region is FR1 consisting of an amino acid sequence having 70% or more sequence identity with the amino acid sequence of the 1st to 24th positions of SEQ ID NO:21, the 1st to 24th positions of SEQ ID NO:23, the 1st to 24th positions of SEQ ID NO:25, or the 1st to 24th positions of SEQ ID NO:27;
  • FR2 consisting of an amino acid sequence having 70% or more sequence identity with the amino acid sequence of positions 33 to 49 of SEQ ID NO: 21, positions 34 to 50 of SEQ ID NO: 23, positions 34 to 50 of SEQ ID NO: 25, or positions 34 to 50 of SEQ ID NO: 27;
  • FR3 consisting of an amino acid sequence having 70% or more sequence identity with the amino acid sequence of positions 59 to 95 of SEQ ID NO:21, positions 60 to 96 of SEQ ID NO:23, positions 59 to 95 of SEQ ID NO:25, or positions 60 to 96 of SEQ ID NO:27;
  • FR4 consisting of an amino acid sequence having 70%
  • the anti-AAV full capsid molecule according to any one of Items 2 to 5, comprising: an FR3 consisting of an amino acid sequence having 70% or more sequence identity with the amino acid sequence of positions 53 to 88 of SEQ ID NO:22, positions 53 to 88 of SEQ ID NO:24, positions 53 to 88 of SEQ ID NO:26, or positions 53 to 88 of SEQ ID NO:28; and an FR4 consisting of an amino acid sequence having 70% or more sequence identity with the amino acid sequence of positions 101 to 110 of SEQ ID NO:22, positions 101 to 110 of SEQ ID NO:24, positions 101 to 109 of SEQ ID NO:26, or positions 98 to 107 of SEQ ID NO:28.
  • Items 7 comprising: an FR3 consisting of an amino acid sequence having 70% or more sequence identity with the amino acid sequence of positions 53 to 88 of SEQ ID NO:22, positions 53 to 88 of SEQ ID NO:24, positions 53 to 88 of SEQ ID NO:26, or positions 53 to 88 of SEQ ID
  • the anti-AAV full capsid molecule of Item 2 wherein the heavy chain variable region comprises the amino acid sequence represented by SEQ ID NO:21, and the light chain variable region comprises the amino acid sequence represented by SEQ ID NO:22.
  • Item 8. The anti-AAV full capsid molecule of Item 3, wherein the heavy chain variable region comprises the amino acid sequence represented by SEQ ID NO:23, and the light chain variable region comprises the amino acid sequence represented by SEQ ID NO:24.
  • Item 9 The anti-AAV full capsid molecule of Item 4, wherein the heavy chain variable region comprises the amino acid sequence represented by SEQ ID NO:25, and the light chain variable region comprises the amino acid sequence represented by SEQ ID NO:26.
  • Item 11 The anti-AAV full capsid molecule according to any one of Items 1 to 10, which is an IgG antibody, a Fab antibody, a Fab' antibody, an F(ab') 2 antibody, an Fv antibody, an scFv antibody, a dsFv antibody, an scFv-Fc antibody, a dsFv-Fc antibody, a Bis-scFv antibody, a minibody, a diabody, a triabody, or a tetrabody.
  • Item 12 An affinity solid phase for binding to an AAV full capsid, comprising the anti-AAV full capsid molecule according to any one of Items 1 to 11, and a solid phase material on which the anti-AAV full capsid molecule is immobilized.
  • Item 13 A method for capturing an AAV full capsid, comprising a step 1 of contacting a sample containing an AAV empty capsid and an AAV full capsid with the AAV full capsid-binding affinity solid phase according to Item 12, and capturing the AAV full capsid.
  • Item 16. An expression cassette or recombinant vector comprising the nucleic acid according to Item 15.
  • Item 17. A transformant obtained by transforming a host with the expression cassette or recombinant vector according to Item 16.
  • Item 18. A method for producing an anti-AAV full capsid molecule, comprising a step of culturing the transformant according to Item 17.
  • an anti-AAV full capsid molecule that has a higher binding affinity to AAV full capsids than to empty AAV capsids. Therefore, according to the present disclosure, it is possible to quantify full capsids using the anti-AAV full capsid molecule.
  • FIG. 1 shows the relationship between the amount of AAV9 full capsid and the ELISA signal (absorbance) using the anti-AAV full capsid molecule (anti-AAV-scFv) of the present disclosure.
  • the anti-AAV full capsid molecule of the present disclosure is an antibody having a higher binding affinity to AAV full capsid than to AAV empty capsid. That is, the anti-AAV full capsid molecule of the present disclosure is a polypeptide having a higher binding affinity to AAV full capsid than to AAV empty capsid, and has a heavy chain variable region including a heavy chain complementarity determining region and a light chain variable region including a light chain complementarity determining region that show a higher binding affinity to AAV full capsid than to AAV empty capsid.
  • the anti-AAV full capsid molecule of the present disclosure is a polypeptide having a higher binding affinity to AAV full capsid than to AAV empty capsid, and has a heavy chain variable region including a predetermined heavy chain complementarity determining region and a light chain variable region including a predetermined light chain complementarity determining region.
  • AAV serotype targeted by the anti-AAV full capsid molecule of the present disclosure is not particularly limited. Specific serotypes include AAV1, AAV2, AAV3a, AAV3b, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAVrh.10, AAV11, AAV12, and AAV13, and preferably AAV9.
  • An empty AAV capsid is an empty outer shell of an AAV that does not contain any nucleic acid inside.
  • a typical example of an empty AAV capsid is a vesicle used to package a target gene (foreign gene) to be delivered to a cell of a therapeutic target.
  • An AAV full capsid is an AAV capsid that contains nucleic acid inside.
  • nucleic acid examples include the viral genome of the AAV, nucleic acid medicines (antisense oligonucleotides, RNAi, aptamers, decoys, etc.), and vectors into which genes for gene therapy have been introduced.
  • the anti-AAV full capsid molecule of the present disclosure has higher binding affinity to AAV full capsid than to AAV empty capsid.
  • the anti-AAV full capsid molecule of the present disclosure has a higher binding affinity to AAV full capsid than to AAV empty capsid can be confirmed by the fact that when the anti-AAV full capsid molecule of the present disclosure is contacted with an AAV empty capsid or an AAV full capsid under the same conditions, the amount of AAV full capsid bound is greater than the amount of AAV empty capsid bound.
  • the anti-AAV full capsid molecule of the present disclosure is prepared in a form with an affinity tag, and contacted with an AAV empty capsid or an AAV full capsid under the same conditions.
  • the anti-AAV full capsid molecule bound to the capsid is then captured with an antibody (anti-affinity tag antibody) that is specific to the affinity tag and has a signal group (e.g., a fluorescent group, etc.), and the signal intensity (e.g., absorbance based on the fluorescent group) based on the signal group of the anti-affinity tag antibody that captured the anti-AAV full capsid molecule can be confirmed.
  • an antibody anti-affinity tag antibody
  • a signal group e.g., a fluorescent group, etc.
  • the signal intensity e.g., absorbance based on the fluorescent group
  • the degree of binding to AAV full capsid include, when the anti-AAV full capsid molecule is contacted with the AAV capsid at pH 7 (25°C) for 1 hour at 25°C, the binding to AAV full capsid based on the above absorbance is 1.5 times or more, specifically 1.5 to 5 times, preferably 2 to 5 times, more preferably 2.5 to 5 times, even more preferably 3 to 5 times, 3.5 to 5 times, and even more preferably 4 to 5 times, of the binding to the empty AAV capsid.
  • the anti-AAV full capsid molecule of the present disclosure typically comprises three heavy chain complementarity determining regions (CDR1, CDR2, and CDR3 from the N-terminus) and three light chain complementarity determining regions (CDR1, CDR2, and CDR3 from the N-terminus).
  • the anti-AAV full capsid molecule of the present disclosure includes a first anti-AAV full capsid molecule shown in [1] of Table 1, a second anti-AAV full capsid molecule shown in [2], a third anti-AAV full capsid molecule shown in [3], and a fourth anti-AAV full capsid molecule shown in [4].
  • the first anti-AAV full capsid molecule comprises a heavy chain variable region including, as a heavy chain complementarity determining region, CDR1 having an amino acid sequence represented by SEQ ID NO:1, CDR2 having an amino acid sequence represented by SEQ ID NO:2, and CDR3 having an amino acid sequence having 90% or more sequence identity with the amino acid sequence represented by SEQ ID NO:3, and a light chain variable region including, as a light chain complementarity determining region, CDR1 having an amino acid sequence represented by SEQ ID NO:4, CDR2 consisting of RAS, and CDR3 having an amino acid sequence having 90% or more sequence identity with the amino acid sequence represented by SEQ ID NO:5.
  • the second anti-AAV full capsid molecule comprises a heavy chain variable region including, as a heavy chain complementarity determining region, CDR1 consisting of the amino acid sequence represented by SEQ ID NO:6, CDR2 consisting of the amino acid sequence represented by SEQ ID NO:7, and CDR3 consisting of an amino acid sequence having 90% or more sequence identity with the amino acid sequence represented by SEQ ID NO:8, and a light chain variable region including, as a light chain complementarity determining region, CDR1 consisting of the amino acid sequence represented by SEQ ID NO:9, CDR2 consisting of RAS, and CDR3 consisting of an amino acid sequence having 90% or more sequence identity with the amino acid sequence represented by SEQ ID NO:10.
  • the second anti-AAV full capsid molecule is preferred in that it has remarkable binding specificity to AAV full capsids.
  • the third anti-AAV full capsid molecule comprises a heavy chain variable region including, as a heavy chain complementarity determining region, CDR1 having an amino acid sequence represented by SEQ ID NO:11, CDR2 having an amino acid sequence represented by SEQ ID NO:12, and CDR3 having an amino acid sequence having 90% or more sequence identity with the amino acid sequence represented by SEQ ID NO:13, and a light chain variable region including, as a light chain complementarity determining region, CDR1 having an amino acid sequence represented by SEQ ID NO:14, CDR2 consisting of QAS, and CDR3 having an amino acid sequence having 90% or more sequence identity with the amino acid sequence represented by SEQ ID NO:15.
  • the fourth anti-AAV full capsid molecule comprises a heavy chain variable region including, as a heavy chain complementarity determining region, CDR1 having the amino acid sequence represented by SEQ ID NO: 16, CDR2 having the amino acid sequence represented by SEQ ID NO: 17, and CDR3 having an amino acid sequence having 90% or more sequence identity with the amino acid sequence represented by SEQ ID NO: 18, and a light chain variable region including, as a light chain complementarity determining region, CDR1 having the amino acid sequence represented by SEQ ID NO: 19, CDR2 consisting of RAS, and CDR3 having the amino acid sequence represented by SEQ ID NO: 20.
  • sequence identity refers to the value of amino acid sequence identity obtained by the bl2seq program (Tatiana A. Tatsusova, Thomas L. Madden, FEMS Microbiol. Lett., Vol. 174, pp. 247-250, 1999) of BLAST PACKAGE [sgi32 bit edition, Version 2.0.12; available from the National Center for Biotechnology Information (NCBI)].
  • NCBI National Center for Biotechnology Information
  • Basic amino acids lysine, arginine, histidine
  • Acidic amino acids glutamic acid, aspartic acid
  • Neutral amino acids glycine, alanine, serine, threonine, methionine, cysteine, phenylalanine, tryptophan, tyrosine, leucine, isoleucine, valine, glutamine, asparagine, proline
  • the neutral amino acids can also be classified into those having polar side chains (asparagine, glutamine, serine, threonine, tyrosine, cysteine), those having non-polar side chains (glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), those having amide-containing side chains (asparagine, glutamine), those having sulfur-containing side chains (methionine, cysteine), those having aromatic side chains (phenylalanine, tryptophan,
  • Methods for replacing a specific amino acid in an amino acid sequence with another amino acid include, for example, site-directed mutagenesis (Hashimoto-Gotoh T. et al., Gene, Vol.152, pp.271-275(1995); Zoller MJ. et al., Methods Enzymol.Vol.100, pp.468-500(1983), Kramer W. et al., Nucleic Acids . Res. Vol. 12, p. 9441-9456 (1984); Kramer W. et al., Methods. Enzymol. Vol. 154, p. 350-367 (1987); Kunkel TA., Proc Natl Acad Sci USA., Vol. 82, p.
  • amino acid substitutions can be made in the amino acid sequence of the CDR using this site-directed mutagenesis method.
  • a method for substituting with other amino acids also includes the library technique described in WO2005/080432.
  • the framework regions of the heavy chain variable region and the light chain variable region of the first to fourth anti-AAV full capsid molecules are not particularly limited, as long as the anti-AAV full capsid molecules have higher binding affinity to AAV full capsid than to AAV empty capsid, and the framework region (FR) of an antibody from any animal (human and non-human, preferably rabbit) can be used.
  • the first through fourth anti-AAV full capsid molecules preferably comprise:
  • the heavy chain variable region is FR1 consisting of an amino acid sequence having 70% or more sequence identity with the amino acid sequence of the 1st to 24th positions of SEQ ID NO:21, the 1st to 24th positions of SEQ ID NO:23, the 1st to 24th positions of SEQ ID NO:25, or the 1st to 24th positions of SEQ ID NO:27;
  • FR2 consisting of an amino acid sequence having 70% or more sequence identity with the amino acid sequence of positions 33 to 49 of SEQ ID NO: 21, positions 34 to 50 of SEQ ID NO: 23, positions 34 to 50 of SEQ ID NO: 25, or positions 34 to 50 of SEQ ID NO: 27;
  • FR3 consisting of an amino acid sequence having 70% or more sequence identity with the amino acid sequence of positions 59 to 95 of SEQ ID NO:21, positions 60 to 96 of SEQ ID NO:23, positions 59 to 95 of SEQ ID NO:25, or positions 60 to 96 of SEQ
  • sequence identity of 70% or more may vary depending on the full length of the reference amino acid sequence, but are preferably 80% or more or 85% or more, more preferably 90% or more, even more preferably 92% or more, even more preferably 94% or more or 95% or more, even more preferably 96% or more or 97% or more, and most preferably 100%.
  • variable regions More preferably, the first anti-AAV full capsid molecule has a heavy chain variable region comprising the amino acid sequence represented by SEQ ID NO:21 and a light chain variable region comprising the amino acid sequence represented by SEQ ID NO:22.
  • SEQ ID NO:21 of the heavy chain variable region is composed of, from the N-terminus, ⁇ FR1 consisting of the amino acid sequence of positions 1 to 24 ⁇ - ⁇ CDR1 consisting of the amino acid sequence of positions 25 to 32 (corresponding to CDR1 of SEQ ID NO:1) ⁇ - ⁇ FR2 consisting of the amino acid sequence of positions 33 to 49 ⁇ - ⁇ CDR2 consisting of the amino acid sequence of positions 50 to 58 (corresponding to CDR2 of SEQ ID NO:2) ⁇ - ⁇ FR3 consisting of the amino acid sequence of positions 59 to 95 ⁇ - ⁇ CDR3 consisting of the amino acid sequence of positions 96 to 108 (corresponding to CDR3 of SEQ ID NO:3) ⁇ - ⁇ FR4 consisting of the amino acid sequence of positions 109 to 119 ⁇ .
  • the light chain variable region of SEQ ID NO:22 is composed of, from the N-terminus, ⁇ FR1 consisting of the amino acid sequence of positions 1 to 26 ⁇ - ⁇ CDR1 consisting of the amino acid sequence of positions 27 to 32 (corresponding to CDR1 of SEQ ID NO:4) ⁇ - ⁇ FR2 consisting of the amino acid sequence of positions 33 to 49 ⁇ - ⁇ CDR2 consisting of the amino acid sequence of positions 50 to 52 ⁇ - ⁇ FR3 consisting of the amino acid sequence of positions 53 to 88 of SEQ ID NO:22 ⁇ - ⁇ CDR3 consisting of the amino acid sequence of positions 89 to 100 (corresponding to CDR3 of SEQ ID NO:5) ⁇ - ⁇ FR4 consisting of the amino acid sequence of positions 101 to 110 of SEQ ID NO:22 ⁇ .
  • the second anti-AAV full capsid molecule has a heavy chain variable region that includes the amino acid sequence represented by SEQ ID NO:23 and a light chain variable region that includes the amino acid sequence represented by SEQ ID NO:24.
  • the heavy chain variable region sequence number 23 is composed of, from the N-terminus, ⁇ FR1 consisting of the amino acid sequence of positions 1 to 24 ⁇ - ⁇ CDR1 consisting of the amino acid sequence of positions 25 to 33 (corresponding to CDR1 of sequence number 6) ⁇ - ⁇ FR2 consisting of the amino acid sequence of positions 34 to 50 ⁇ - ⁇ CDR2 consisting of the amino acid sequence of positions 51 to 59 (corresponding to CDR2 of sequence number 7) ⁇ - ⁇ FR3 consisting of the amino acid sequence of positions 60 to 96 ⁇ - ⁇ CDR3 consisting of the amino acid sequence of positions 97 to 108 (corresponding to CDR3 of sequence number 8) ⁇ - ⁇ FR4 consisting of the amino acid sequence of positions 109 to 119 ⁇ .
  • the light chain variable region of SEQ ID NO:24 is composed of, from the N-terminus, ⁇ FR1 consisting of the amino acid sequence of positions 1 to 26 ⁇ - ⁇ CDR1 consisting of the amino acid sequence of positions 27 to 32 (corresponding to CDR1 of SEQ ID NO:9) ⁇ - ⁇ FR2 consisting of the amino acid sequence of positions 33 to 49 ⁇ - ⁇ CDR2 consisting of the amino acid sequence of positions 50 to 52 ⁇ - ⁇ FR3 consisting of the amino acid sequence of positions 53 to 88 ⁇ - ⁇ CDR3 consisting of the amino acid sequence of positions 89 to 100 (corresponding to CDR3 of SEQ ID NO:10) ⁇ - ⁇ FR4 consisting of the amino acid sequence of positions 101 to 110 ⁇ .
  • the third anti-AAV full capsid molecule has a heavy chain variable region that includes the amino acid sequence represented by SEQ ID NO:25 and a light chain variable region that includes the amino acid sequence represented by SEQ ID NO:26.
  • the heavy chain variable region sequence number 25 is composed of, from the N-terminus, ⁇ FR1 consisting of the amino acid sequence of positions 1 to 24 ⁇ - ⁇ CDR1 consisting of the amino acid sequence of positions 25 to 33 (corresponding to CDR1 of sequence number 11) ⁇ - ⁇ FR2 consisting of the amino acid sequence of positions 34 to 50 ⁇ - ⁇ CDR2 consisting of the amino acid sequence of positions 51 to 58 (corresponding to CDR2 of sequence number 12) ⁇ - ⁇ FR3 consisting of the amino acid sequence of positions 59 to 95 ⁇ - ⁇ CDR3 consisting of the amino acid sequence of positions 96 to 106 (corresponding to CDR3 of sequence number 13) ⁇ - ⁇ FR4 consisting of the amino acid sequence of positions 107 to 117 ⁇ .
  • the light chain variable region of SEQ ID NO:26 is composed of, from the N-terminus, ⁇ FR1 consisting of the amino acid sequence of positions 1 to 26 ⁇ - ⁇ CDR1 consisting of the amino acid sequence of positions 27 to 32 (corresponding to CDR1 of SEQ ID NO:14) ⁇ - ⁇ FR2 consisting of the amino acid sequence of positions 33 to 49 ⁇ - ⁇ CDR2 consisting of the amino acid sequence of positions 50 to 52 ⁇ - ⁇ FR3 consisting of the amino acid sequence of positions 53 to 88 ⁇ - ⁇ CDR3 consisting of the amino acid sequence of positions 89 to 100 (corresponding to CDR3 of SEQ ID NO:15) ⁇ - ⁇ FR4 consisting of the amino acid sequence of positions 101 to 109 ⁇ .
  • the fourth anti-AAV full capsid molecule has a heavy chain variable region that includes an amino acid sequence represented by SEQ ID NO:27 and a light chain variable region that includes an amino acid sequence represented by SEQ ID NO:28.
  • the heavy chain variable region of sequence number 27 is composed of, from the N-terminus, ⁇ FR1 consisting of the amino acid sequence of positions 1 to 24 ⁇ - ⁇ CDR1 consisting of the amino acid sequence of positions 25 to 33 (corresponding to CDR1 of sequence number 16) ⁇ - ⁇ FR2 consisting of the amino acid sequence of positions 34 to 50 of sequence number 27 ⁇ - ⁇ CDR2 consisting of the amino acid sequence of positions 51 to 59 (corresponding to CDR2 of sequence number 17) ⁇ - ⁇ FR3 consisting of the amino acid sequence of positions 60 to 96 of sequence number 27 ⁇ - ⁇ CDR3 consisting of the amino acid sequence of positions 97 to 112 (corresponding to CDR3 of sequence number 18) ⁇ - ⁇ FR4 consisting of the amino acid sequence of positions 113 to 123 of sequence number 27 ⁇ .
  • the light chain variable region of SEQ ID NO:28 is composed of, from the N-terminus, ⁇ FR1 consisting of the amino acid sequence of positions 1 to 26 ⁇ - ⁇ CDR1 consisting of the amino acid sequence of positions 27 to 32 (corresponding to CDR1 of SEQ ID NO:19) ⁇ - ⁇ FR2 consisting of the amino acid sequence of positions 33 to 49 ⁇ - ⁇ CDR2 consisting of the amino acid sequence of positions 50 to 52 ⁇ - ⁇ FR3 consisting of the amino acid sequence of positions 53 to 88 ⁇ - ⁇ CDR3 consisting of the amino acid sequence of positions 89 to 97 (corresponding to CDR3 of SEQ ID NO:20) ⁇ - ⁇ FR4 consisting of the amino acid sequence of positions 98 to 107 ⁇ .
  • the anti-AAV full capsid molecule of the present disclosure may be a complete antibody or a low molecular weight antibody (an antibody having a smaller molecular weight than a complete antibody).
  • the anti-AAV full capsid molecule of the present disclosure is a complete antibody
  • its isotype is not particularly limited, and examples include IgG (IgG1, IgG2, IgG3, IgG4), IgA (IgA1, IgA2), IgM, IgD, and IgE.
  • the anti-AAV full capsid molecule of the present disclosure is a low molecular weight antibody
  • specific examples thereof include a Fab antibody (about 55 kDa), a Fab' antibody (about 55 kDa), an F(ab') 2 antibody (about 110 kDa), an Fv antibody (about 25 kDa), an scFv antibody (about 25 kDa), a dsFv antibody (about 25 kDa), an scFv-Fc antibody (about 105 kDa), a dsFv-Fc antibody (about 105 kDa), a Bis-scFv antibody (about 50 kDa), a minibody (about 80 kDa), a diabody (about 55 kDa), a triabody (about 75 kDa), a tetrabody (about 100 kDa), and the like.
  • the anti-AAV full capsid molecule of the present disclosure also includes multispecific antibodies (e.g., bispecific antibodies) so long as it has a heavy chain variable region containing a predetermined heavy chain complementarity determining region and a light chain variable region containing a predetermined light chain complementarity determining region.
  • multispecific antibodies e.g., bispecific antibodies
  • These fragment antibodies and multispecific antibodies can be produced according to conventionally known methods.
  • the anti-AAV full capsid molecule of the present disclosure is typically an isolated monoclonal antibody.
  • the method for producing the monoclonal antibody is not particularly limited, but may be, for example, the hybridoma method described in "Kohler G, Milstein C., Nature. 1975 Aug 7;256(5517):495-497.”; the recombinant method described in "Clackson et al., Nature. 1991 Aug 7;256(5517):495-497.”; Aug 15; 352 (6336): 624-628. or Marks et al., J Mol Biol. 1991 Dec 5; 222 (3): 581-597., or the method described in Protein Experiment Handbook, Yodosha (2003): 92-96.
  • the anti-AAV full capsid molecule of the present disclosure may contain other configurations in addition to the antibody components (the above-mentioned complementarity determining regions, the above-mentioned framework, and the portions other than the complementarity determining regions and framework constituting the above-mentioned "1-6. Specific Form of the Anti-AAV Full Capsid Molecule"), so long as it has a higher binding affinity to an AAV full capsid than to an AAV empty capsid.
  • Anti-AAV full capsid molecules of the present disclosure that include other components include conjugated antibodies to which various compounds such as polyethylene glycol, radioactive substances, and toxins are bound as other components, antibodies to which modified glycans are bound as other components, and fusion antibodies to which another protein is fused as other components.
  • Preferred examples of other configurations include a hinge region, a spacer, a purification tag for enabling purification of the anti-AAV full capsid molecule of the present disclosure, and an immobilization modification group for enabling immobilization of the anti-AAV full capsid molecule of the present disclosure to a solid phase. These configurations may be used alone or in combination of two or more types.
  • the number of amino acid residues constituting the hinge region is not particularly limited, but may be, for example, 1 to 25 aa, and preferably 5 to 20 aa.
  • Specific examples of hinge regions include EPKTPKPQ, AHHSEDPS, EPTPPQPQPQPQPNPTTE, etc.
  • Any suitable length of spacer can be selected, for example 1 to 6 amino acids, preferably 2 to 5 amino acids.
  • the purification tag is directly or indirectly bound to the antibody component via an arbitrary linker group.
  • the purification tag include a histidine tag (an oligohistidine consisting of 6 or more, preferably 6 to 10, histidine residues, which reversibly chelates to a solid phase having a central metal ion such as nickel (Ni 2+ ) or cobalt (Co 2+ ) on its surface), a strep tag (a tag consisting of WSHPQFEK, which reversibly binds to a solid phase having streptavidin on its surface), a flag tag (a tag consisting of DYKDDDDK or DYKDHD-G-DYKDHD-I-DYKDDDDK, which reversibly binds to a solid phase having a flag tag recognition site on its surface), a spot tag (a tag consisting of PDRVRAVSHWSS, which reversibly binds to a solid phase having a spot tag recognition site on its surface), and a
  • the modification group for immobilization is bound to the antibody component directly or indirectly via an optional linker group.
  • the modification group for immobilization includes an amino group (a group that, together with the carboxyl group of a polypeptide, forms a carbamoyl group; it is immobilized via the amino group to a solid phase having an active ester group or an epoxy group immobilized on its surface), a thiol group (immobilized by a Michael addition reaction to a solid phase whose surface is modified with a maleimide group), a cyclopentadienyl group (immobilized by a Diels-Alder reaction to a solid phase whose surface is modified with a quinone group), and a biotinyl group (immobilized by biotin-avidin interaction to a solid phase whose surface is modified with an avidin group).
  • an amino group a group that, together with the carboxyl group of a polypeptide, forms a carbamoyl group; it is immobilized via the
  • oxyamino group immobilized by Schiff base on a solid phase surface-modified with formyl group
  • cysteine residue immobilized by thiazoline ring formation on a solid phase surface-modified with formyl group, or immobilized by transesterification on a solid phase surface-modified with benzylthioester
  • carboxyl group modified group with 2-(2-pyridinyldithio)-ethanamine (PDEA) immobilized by disulfide bond on a solid phase surface-modified with thiol group
  • the above purification tags or immobilization modification groups can be introduced into antibody components by standard methods, thereby synthesizing the anti-AAV full capsid molecule of the present disclosure.
  • AAV full capsid-binding affinity solid phase The AAV full capsid-binding affinity solid phase of the present disclosure includes the above-mentioned "1. Anti-AAV full capsid molecule” and a solid phase material to which the anti-AAV full capsid molecule is immobilized (also referred to herein simply as "solid phase").
  • the material of the solid phase is not particularly limited, and examples include resins (agarose, sepharose, dextran, silica gel, polyacrylamide, polystyrene, polyethylene, polypropylene, polyester, polyacrylonitrile, (meth)acrylic acid-based polymers, fluororesins, metal complex resins, etc.), glass, metals, magnetic materials, etc.
  • resins agarose, sepharose, dextran, silica gel, polyacrylamide, polystyrene, polyethylene, polypropylene, polyester, polyacrylonitrile, (meth)acrylic acid-based polymers, fluororesins, metal complex resins, etc.
  • the shape of the solid phase material is not particularly limited and can be appropriately determined depending on the mode of use of the affinity solid phase for binding to AAV full capsid of the present disclosure.
  • Examples of the shape of the solid phase include flat, particulate, fibrous, etc.
  • the flat solid phase may form a chip or the bottom surface of a container, well, etc.
  • the particulate or fibrous solid phase may be packed in a column.
  • the method for capturing AAV full capsid of the present disclosure includes a step 1 of contacting a sample containing an AAV empty capsid and an AAV full capsid with the affinity solid phase for binding to an AAV full capsid described above in "2. Affinity solid phase for binding to AAV full capsid" and capturing the AAV full capsid.
  • a sample containing empty AAV capsid and AAV full capsid is contacted with the affinity solid phase to selectively capture the AAV full capsid in the sample.
  • the conditions for contacting the sample with the solid phase are not particularly limited, and include, for example, neutral conditions (e.g., pH 6.5 to 7.7 at 25°C) and, for example, room temperature (preferably, 15 to 30°C), for example, 1 minute to 3 hours.
  • the AAV full capsid capture method disclosed herein can be used, for example, in a method for quantifying AAV full capsids in the above sample, or in a method for separating AAV full capsids in the above sample.
  • the method may further include step 2 of quantifying the captured AAV full capsid by enzyme-linked immunosorbent assay.
  • a known method may be used for the enzyme-linked immunosorbent assay, and specifically, any of a direct method, an indirect method, a sandwich method, and a competitive method may be used.
  • the binding between the affinity solid phase and the AAV full capsid can be detected based on a signal emitted by a signal group such as a fluorescent label, and therefore the AAV full capsid can be quantified based on the intensity of the signal.
  • the method may further include step 3 of separating and recovering the captured AAV full capsid.
  • the solid phase material may be used in a form packed in a chromatography column.
  • the AAV full capsid captured on the affinity solid phase is recovered by elution.
  • the elution method include elution by adjusting the pH (e.g., acid elution, alkaline elution), elution by adjusting the salt concentration (e.g., elution with a high salt concentration), etc.
  • the recovered AAV full capsid fraction may be further purified by any purification method as necessary.
  • the recovered AAV full capsid fraction or its purified fraction may be powdered by freeze drying, vacuum drying, spray drying, etc. as necessary.
  • Anti-AAV full capsid molecule can be appropriately prepared and designed by a person skilled in the art according to the amino acid sequence of the anti-AAV full capsid molecule of the present disclosure.
  • the nucleic acid of the present disclosure may be DNA or RNA.
  • nucleic acid disclosed herein can be appropriately designed by a person skilled in the art according to the amino acid sequence of the complementarity determining region described above in "1-3. Complementarity determining region.”
  • the base sequences encoding CDR1 represented by SEQ ID NO:1, CDR2 represented by SEQ ID NO:2, and CDR3 represented by SEQ ID NO:3 include the base sequences represented by SEQ ID NO:29, 30, and 31, respectively, and DNA base sequences that hybridize under stringent conditions with DNA consisting of base sequences complementary to these base sequences.
  • the base sequences encoding CDR1 represented by SEQ ID NO:4, CDR2 consisting of RAS, and CDR3 represented by SEQ ID NO:5 include the base sequence represented by SEQ ID NO:32, agggcatcc, and the base sequence represented by SEQ ID NO:33, respectively, and DNA base sequences that hybridize under stringent conditions with DNA consisting of base sequences complementary to these base sequences.
  • the base sequences encoding CDR1 represented by SEQ ID NO:6, CDR2 represented by SEQ ID NO:7, and CDR3 represented by SEQ ID NO:8 include the base sequences represented by SEQ ID NO:34, 35, and 36, respectively, and DNAs consisting of complementary base sequences to these base sequences, and base sequences of DNAs that hybridize under stringent conditions.
  • the base sequences encoding CDR1 represented by SEQ ID NO:9, CDR2 consisting of RAS, and CDR3 represented by SEQ ID NO:10 include the base sequence represented by SEQ ID NO:37, agggcatcc, and the base sequence represented by SEQ ID NO:38, respectively, and DNAs consisting of complementary base sequences to these base sequences, and base sequences of DNAs that hybridize under stringent conditions.
  • the base sequences encoding CDR1 represented by SEQ ID NO:11, CDR2 represented by SEQ ID NO:12, and CDR3 represented by SEQ ID NO:13 include the base sequences represented by SEQ ID NOs:39, 40, and 41, respectively, and DNAs consisting of complementary base sequences to these base sequences, and DNA base sequences that hybridize under stringent conditions to these base sequences.
  • the base sequences encoding CDR1 represented by SEQ ID NO:14, CDR2 consisting of QAS, and CDR3 represented by SEQ ID NO:15 include the base sequence represented by SEQ ID NO:42, caggcatcc, and the base sequence represented by SEQ ID NO:43, respectively, and DNAs consisting of complementary base sequences to these base sequences, and DNA base sequences that hybridize under stringent conditions to these base sequences.
  • the base sequences encoding CDR1 represented by SEQ ID NO:16, CDR2 represented by SEQ ID NO:17, and CDR3 represented by SEQ ID NO:18 include the base sequences represented by SEQ ID NOs:44, 45, and 46, respectively, and DNAs consisting of complementary base sequences to these base sequences, and DNA base sequences that hybridize under stringent conditions.
  • the base sequences encoding CDR1 represented by SEQ ID NO:19, CDR2 consisting of RAS, and CDR3 represented by SEQ ID NO:20 include the base sequence represented by SEQ ID NO:47, agggcatcc, and the base sequence represented by SEQ ID NO:48, respectively, and DNAs consisting of complementary base sequences to these base sequences, and DNA base sequences that hybridize under stringent conditions.
  • the base sequence of the nucleic acid of the present disclosure can be appropriately designed by a person skilled in the art according to the amino acid sequence of the framework region described in "1-4. Framework Region” above, or the amino acid sequence of the variable region described in “1-5. Specific Examples of Variable Regions" above.
  • examples of base sequences encoding the heavy chain variable region and the light chain variable region include base sequences represented by SEQ ID NOs: 49 and 50, which encode the amino acid sequences represented by SEQ ID NOs: 21 and 22, respectively, and base sequences of DNA that hybridize under stringent conditions with DNA consisting of base sequences complementary to these base sequences.
  • examples of base sequences encoding the heavy chain variable region and the light chain variable region include base sequences represented by SEQ ID NOs: 51 and 52, which encode the amino acid sequences represented by SEQ ID NOs: 23 and 24, respectively, and base sequences of DNA that hybridize under stringent conditions with DNA consisting of base sequences complementary to these base sequences.
  • the base sequences encoding the heavy chain variable region and the light chain variable region include the base sequences represented by SEQ ID NOs: 53 and 54, which encode the amino acid sequences represented by SEQ ID NOs: 25 and 26, respectively, and the base sequences of DNA that hybridize under stringent conditions with DNA consisting of base sequences complementary to these base sequences.
  • the base sequences encoding the heavy chain variable region and the light chain variable region include the base sequences represented by SEQ ID NOs: 55 and 56, which encode the amino acid sequences represented by SEQ ID NOs: 27 and 28, respectively, and the base sequences of DNA that hybridize under stringent conditions with DNA consisting of base sequences complementary to these base sequences.
  • stringent conditions refers to conditions in which the mixture is incubated at 50°C to 65°C for 4 hours to overnight in 6xSSC (1xSSC is 0.15M NaCl, 0.015M sodium citrate, pH 7.0) containing 0.5% SDS, 5x Denhartz's (0.1% bovine serum albumin (BSA), 0.1% polyvinylpyrrolidone, 0.1% Ficoll 400) and 100 ⁇ g/ml salmon sperm DNA.
  • BSA bovine serum albumin
  • polyvinylpyrrolidone 0.1% Ficoll 400
  • a nylon membrane on which a DNA library or a cDNA library is immobilized is prepared, and the nylon membrane is blocked at 65°C in a prehybridization solution containing 6xSSC, 0.5% SDS, 5x Denhartz's, and 100 ⁇ g/ml salmon sperm DNA. Then, each 32P -labeled probe is added and incubated overnight at 65° C. The nylon membrane is washed in 6 ⁇ SSC at room temperature for 10 minutes, in 2 ⁇ SSC containing 0.1% SDS at room temperature for 10 minutes, and in 0.2 ⁇ SSC containing 0.1% SDS at 45° C. for 30 minutes, and then autoradiography is performed to detect DNA that has specifically hybridized with the probe.
  • the base sequence of the nucleic acid disclosed herein can be further appropriately designed according to the other configurations described above in "1-7.
  • Other Configurations that are represented by amino acid sequences.
  • the nucleic acid of the present disclosure can also be obtained by using the nucleic acid encoding the anti-AAV full capsid molecule as a template to obtain at least the region encoding the anti-AAV full capsid molecule by PCR or the like.
  • the nucleic acid of the present disclosure can also be artificially synthesized by gene synthesis methods.
  • the nucleic acid of the present disclosure may further include at least one of a base sequence encoding a start codon and a stop codon.
  • Methods for obtaining the nucleic acids disclosed herein include methods based on hybridization.
  • the nucleic acids disclosed herein include various nucleic acids resulting from codon degeneracy.
  • Various nucleic acids encoding the same amino acid sequence can be artificially produced easily using known genetic engineering techniques. For example, in the genetic engineering production of a polypeptide, if the codons used in the original gene encoding the target protein are used infrequently in the host, the expression level of the protein may be low. In such cases, the codon usage frequency can be optimized for the host without changing the encoded amino acid sequence, thereby achieving high expression of the target protein.
  • the sum of the host optimal codon usage frequencies for each codon can be used as an index of codon usage frequency.
  • An optimal codon is defined as the codon with the highest usage frequency among the codons corresponding to the same amino acid. There are no particular limitations on the codon usage frequency as long as it is optimized for the host, but the following is an example of an optimal codon for E.
  • coli F: phenylalanine (ttt), L: leucine (ctg), I: isoleucine (att), M: methionine (atg), V: valine (gtg), Y: tyrosine (tat), stop codon (taa), H: histidine (cat), Q: glutamine (cag), N: asparagine (aat), K: lysine (aaa), D: aspartic acid (gat), E: glutamic acid (gaa), S: serine (agc), P: proline (ccg), T: threonine (acc), A: alanine (gcg), C: cysteine (tgc), W: tryptophan (tgg), R: arginine (cgc), G: glycine (ggc).
  • Expression Cassette or Recombinant Vector An expression cassette or recombinant vector containing the nucleic acid described in "4. Nucleic Acid” above (hereinafter also referred to as “expression cassette of the present disclosure” or “recombinant vector of the present disclosure”) contains a nucleic acid encoding a polypeptide of the present disclosure.
  • the expression cassette or recombinant vector of the present disclosure can be obtained by linking a promoter and a terminator to the nucleic acid of the present disclosure, or by inserting the expression cassette or nucleic acid of the present disclosure into an expression vector.
  • the expression cassette or recombinant vector of the present disclosure may contain, as control elements, a promoter and a terminator, as well as transcription elements such as an enhancer, a CCAAT box, a TATA box, and an SPI site, as necessary. These control elements may be operably linked to the DNA of the present disclosure. "Operably linked" means that the various control elements that regulate the DNA of the present disclosure are linked to the DNA of the present disclosure in a state that allows them to operate in a host cell.
  • the expression cassette or recombinant vector of the present disclosure can be configured to contain a combination of a base sequence encoding a protease recognition sequence and a base sequence encoding an N-terminal sequence and/or a C-terminal sequence.
  • the expression vector is preferably one constructed for genetic recombination from a phage, plasmid, or virus that can grow autonomously in a host.
  • Such expression vectors are well known, and those skilled in the art can select and use an appropriate combination with a host cell.
  • examples of the vector include pBluescript (pBS) II SK(-) (Stratagene), pSTV vectors (Takara Bio), pUC vectors (Takara Bio), pET vectors (Sigma-Aldrich Japan LLC), pGEX vectors (Global Life Science Technologies Japan (Cytiva)), pCold vectors (Takara Bio), pHY300PLK (Takara Bio), pUB110 (Mckenzie, T.
  • examples of the vectors include pUC19 (manufactured by Takara Bio), P66 (Chlamydomonas Center), P-322 (Chlamydomonas Center), pPha-T1 (see Yangmin Gong, et al., Journal of Basic Microbiology, 2011, vol. 51, pp. 666-672), and pJET1 (manufactured by Thermo Fisher Scientific).
  • examples of the vectors include pRI-based vectors (manufactured by Takara Bio), pBI-based vectors (manufactured by Clontech), and IN3-based vectors (manufactured by Implanta Innovations).
  • Transformant A transformant (hereinafter, sometimes referred to as “the transformant of the present disclosure") can be obtained by transforming a host with the expression cassette or recombinant vector of the present disclosure.
  • the host used to produce the transformant is not particularly limited as long as it is capable of introducing a gene, of autonomous proliferation, and of expressing the genetic traits of the present disclosure.
  • Suitable examples include microorganisms such as bacteria belonging to the genus Escherichia, such as Escherichia coli, the genus Bacillus, such as Bacillus subtilis, and the genus Pseudomonas, such as Pseudomonas putida; actinomycetes; yeast; and filamentous fungi, but may also be animal cells, insect cells, plant cells, and the like.
  • Escherichia coli is particularly preferred.
  • the transformant of the present disclosure can be obtained by introducing an expression cassette or recombinant vector of the present disclosure into a host.
  • the location of introduction of the nucleic acid of the present disclosure is not particularly limited as long as the target gene can be expressed, and may be on a plasmid or on the genome.
  • Specific methods for introducing the expression cassette of the present disclosure or the recombinant vector of the present disclosure include, for example, a recombinant vector method and a genome editing method.
  • the conditions for introducing the expression cassette or recombinant vector of the present disclosure into a host may be appropriately set depending on the type of host, etc.
  • examples of the methods include a method using competent cells treated with calcium ions, the electroporation method, the spheroplast method, and the lithium acetate method.
  • examples of the methods include the electroporation method, the calcium phosphate method, and the lipofection method.
  • examples of the methods include the calcium phosphate method, the lipofection method, and the electroporation method.
  • examples of the methods include the electroporation method, the Agrobacterium method, the particle gun method, and the PEG method.
  • the present disclosure also provides a method for producing the anti-AAV full capsid molecule described above in "1. Anti-AAV full capsid molecule.”
  • the anti-AAV full capsid molecule which is an antibody having a higher binding affinity to the AAV full capsid than to the empty AAV capsid, can be appropriately produced by limited mechanical operations.
  • the anti-AAV full capsid molecule of the present disclosure can be appropriately obtained by a limited mechanical operation of selecting an antibody from an antibody library by affinity selection for AAV full capsid, and confirming that the selected antibody has a higher binding affinity to AAV full capsid than to AAV empty capsid.
  • the anti-AAV full capsid molecule can be obtained by the steps of: immunizing an animal with an AAV capsid protein as an antigen, obtaining an antibody gene from the lymphocytes of the animal, and introducing the obtained antibody genes combining various VH regions and various VL regions into a phagemid vector to construct an antibody library; performing biopanning to select a phage clone having binding affinity to AAV full capsid; and confirming that the binding affinity of the antibody contained in the culture supernatant of the selected phage clone to AAV full capsid is higher than to AAV empty capsid.
  • the anti-AAV full capsid molecule of the present disclosure can be appropriately produced by a finite mechanical operation not only in the case of one having a CDR consisting of an amino acid sequence represented by a specific SEQ ID NO, but also in the case of one having a CDR having a sequence identity of 90% to less than 100% with the amino acid sequence represented by a specific SEQ ID NO.
  • an antibody phage library is produced by introducing an antibody gene having a very limited variation sequence (preferably a sequence of variation due to conservative amino acid substitution) having a sequence identity of 90% to less than 100% with the amino acid sequence represented by a specific SEQ ID NO in the CDR region on the structural domain into a phagemid vector, and as described in the above item 7-1, a phage clone having binding ability to AAV full capsid is selected by biopanning, and the binding ability of the antibody produced by the selected phage clone to AAV full capsid is confirmed to be higher than that to AAV empty capsid, thereby obtaining the anti-AAV full capsid molecule of the present disclosure.
  • a phage clone having binding ability to AAV full capsid is selected by biopanning, and the binding ability of the antibody produced by the selected phage clone to AAV full capsid is confirmed to be higher than that to AAV empty capsid, thereby obtaining the anti-AAV full
  • the anti-AAV full capsid molecule of the present disclosure can be produced by culturing the transformant of the present disclosure.
  • the culture conditions for the transformant of the present disclosure may be appropriately set taking into consideration the nutritional and physiological properties of the host, but liquid culture is preferred. For industrial production, aeration and agitation culture is preferred.
  • the transformant of the present disclosure is cultured, and the culture supernatant or cultured bacterial mass or cultured cells are recovered by centrifugation or other methods. If the polypeptide of the present disclosure has accumulated in the cultured bacterial mass or cells, the bacterial mass or cells can be treated with mechanical methods such as ultrasound or French press, or with a lytic enzyme such as lysozyme, and solubilized as necessary using an enzyme such as protease or a surfactant such as sodium dodecyl sulfate (SDS), to obtain a water-soluble fraction containing the anti-AAV full capsid molecule of the present disclosure.
  • mechanical methods such as ultrasound or French press
  • a lytic enzyme such as lysozyme
  • an enzyme such as protease or a surfactant such as sodium dodecyl sulfate (SDS)
  • the expressed anti-AAV full capsid molecule of the present disclosure may be secreted into the culture medium.
  • the culture medium, water-soluble fraction, or protease-treated product containing the anti-AAV full capsid molecule of the present disclosure obtained as described above may be subjected to a purification process as is, or the anti-AAV full capsid molecule of the present disclosure in the culture medium, water-soluble fraction, or protease-treated product may be concentrated and then subjected to a purification process.
  • Concentration can be performed, for example, by vacuum concentration, membrane concentration, salting out treatment, fractional precipitation using a hydrophilic organic solvent (e.g., methanol, ethanol, and/or acetone), etc.
  • a hydrophilic organic solvent e.g., methanol, ethanol, and/or acetone
  • the purification process for the anti-AAV full capsid molecule of the present disclosure can be carried out by appropriately combining methods such as gel filtration, hydrophobic chromatography, ion exchange chromatography, and affinity chromatography corresponding to the purification tag.
  • the anti-AAV full capsid molecule of the present disclosure purified in this manner may be powdered by freeze-drying, vacuum drying, spray drying, etc., if necessary.
  • phagemid vector treatment with a predetermined restriction enzyme was also performed on the phagemid vector, and each gene treated with the restriction enzyme was inserted into the phagemid vector treated with the restriction enzyme.
  • This recombinant phagemid vector was transformed into E. coli TG-1, and inoculated into 10 ml of 2xYT medium (containing 1% glucose and 50 mg/L ampicillin). The cells were cultured overnight at 37°C and 200 rpm in a 200 ml Erlenmeyer flask (preculture).
  • the preculture solution was inoculated into 50 ml of 2xYT medium (containing 1% glucose and 50 mg/L ampicillin) to an OD600 of 0.1, and cultured at 30°C and 200 rpm with shaking. After culturing until the OD reached approximately 1.0, helper phage VCSM13 was added to the culture solution to a multiplicity of infection (MOI) of 20, and incubated at 37°C for 30 minutes. The mixture was centrifuged at 3000 g for 10 minutes at 37°C, the supernatant was removed, and the mixture was gently suspended in 50 ml of 2xYT medium (containing 50 mg/L ampicillin and 35 mg/L kanamycin).
  • 2xYT medium containing 1% glucose and 50 mg/L ampicillin
  • the mixture was shaken at 30°C and 200 rpm for 12 hours or more to produce phages displaying single-chain antibodies in the culture supernatant.
  • the supernatant was collected by centrifugation, concentrated by PEG precipitation, and a library of phages displaying single-chain antibodies was obtained in 1 ml of PBS.
  • the plate was washed three times with a buffer solution containing 0.1% Tween 20 (137 mmol/l NaCl, 8.1 mmol/l Na 2 HPO 4 , 2.68 mmol/l KCl, 1.47 mmol/l KH 2 PO 4 , pH 7.4).
  • the phage library (about 1.0 ⁇ 10 11 pfu) prepared in (1) above was dissolved and dispersed in a buffer solution (137 mmol/l NaCl, 8.1 mmol/l Na 2 HPO 4 , 2.68 mmol/l KCl, 1.47 mmol/l KH 2 PO 4 , pH 7.4) containing 2% BSA, added to the tube, and incubated for 1 hour at 25° C.
  • a buffer solution 137 mmol/l NaCl, 8.1 mmol/l Na 2 HPO 4 , 2.68 mmol/l KCl, 1.47 mmol/l KH 2 PO 4 , pH 7.4
  • coli TG-1 infected with the phage displaying the single-chain antibody was spread on LB agar medium (ampicillin was added to a final concentration of 50 mg/L) and incubated overnight at 37°C to form colonies. 96 clones were randomly selected from the culture.
  • the 96 clones selected in (2) above were each cultured in 2YT medium at 37°C for 24 hours, and the anti-AAV-scFv contained in the culture supernatant was purified and quantified using His MultiTrap FF according to the protocol.
  • the 96 clones included the first anti-AAV-scFv [1], the second anti-AAV-scFv [2], the third anti-AAV-scFv [3], and the fourth anti-AAV-scFv [4], each of which is composed of the amino acid sequence of the variable region shown in Table 2A and the amino acid sequence of the linker and the amino acid sequence of the tag shown in Table 2B.
  • Each anti-AAV-scFv is composed of the heavy chain variable region, linker, light chain variable region, and tag in this order from the N-terminus.
  • Aqueous solutions of these anti-AAV-scFv [1] to [4] were applied to a plate and shaken at 25° C. for 1 hour (pH approximately 7).
  • Test Example 2 The same procedures as in Test Example 1 were carried out using the second anti-AAV-scFv [2], except that the amount of AAV applied to the plate in step "1" of the experimental procedure in Test Example 1 was changed, and the absorbance at 450 nm and 650 nm was measured for each well, and the value obtained by subtracting the absorbance at 650 nm from the absorbance at 450 nm was used as the absorbance value of the ELISA signal.
  • a graph with absorbance on the ordinate and the amount of AAV applied on the abscissa is shown in Figure 1.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
PCT/JP2024/039335 2023-11-06 2024-11-05 Aavのフルカプシドに対するアフィニティポリペプチド Pending WO2025100417A1 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2025556404A JPWO2025100417A1 (cg-RX-API-DMAC7.html) 2023-11-06 2024-11-05
CN202480069293.0A CN122122177A (zh) 2023-11-06 2024-11-05 针对aav的完整衣壳的亲和多肽

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2023189677 2023-11-06
JP2023-189677 2023-11-06

Publications (1)

Publication Number Publication Date
WO2025100417A1 true WO2025100417A1 (ja) 2025-05-15

Family

ID=95695562

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2024/039335 Pending WO2025100417A1 (ja) 2023-11-06 2024-11-05 Aavのフルカプシドに対するアフィニティポリペプチド

Country Status (3)

Country Link
JP (1) JPWO2025100417A1 (cg-RX-API-DMAC7.html)
CN (1) CN122122177A (cg-RX-API-DMAC7.html)
WO (1) WO2025100417A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026048975A1 (ja) * 2024-08-29 2026-03-05 株式会社ダイセル Aavカプシドに結合する抗体

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO2005080432A2 (en) 2004-02-19 2005-09-01 Genentech, Inc. Cdr-repaired antibodies
CN101426935B (zh) 2001-11-13 2013-08-21 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
JP2013536173A (ja) * 2010-07-16 2013-09-19 フエー・イー・ベー・フエー・ゼツト・ウエー Gpcrの機能的立体構造状態を安定化するタンパク質結合ドメインおよびその使用
JP2015513538A (ja) * 2012-02-22 2015-05-14 イムーンダイアグノスティック・アー・ゲー 酸化的ストレスに苦しむ患者の上皮小体ホルモンを測定する手段および方法
JP2016523821A (ja) * 2013-04-24 2016-08-12 フラウンホーファーゲゼルシャフト ツール フォルデルング デル アンゲヴァンテン フォルシユング エー.フアー. アピコンプレクサ病原体に対する新規ワクチン
JP2021523702A (ja) * 2018-05-04 2021-09-09 オレゴン ヘルス アンド サイエンス ユニバーシティ ヒト抗aav2カプシドポリクローナル抗体エピトープ
WO2021191079A1 (en) 2020-03-24 2021-09-30 Puridify Ltd Characterization of gene therapy vectors
JP2022549679A (ja) * 2019-09-27 2022-11-28 バイオマリン ファーマシューティカル インコーポレイテッド サイズ排除クロマトグラフィー及び多角度光散乱技術を使用した遺伝子療法ウイルス粒子のキャラクタリゼーション
JP2023529417A (ja) * 2020-06-15 2023-07-10 サレプタ セラピューティクス, インコーポレイテッド アデノ関連ウイルス抗体及びそのフラグメント

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
CN101426935B (zh) 2001-11-13 2013-08-21 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
WO2005080432A2 (en) 2004-02-19 2005-09-01 Genentech, Inc. Cdr-repaired antibodies
JP2013536173A (ja) * 2010-07-16 2013-09-19 フエー・イー・ベー・フエー・ゼツト・ウエー Gpcrの機能的立体構造状態を安定化するタンパク質結合ドメインおよびその使用
JP2015513538A (ja) * 2012-02-22 2015-05-14 イムーンダイアグノスティック・アー・ゲー 酸化的ストレスに苦しむ患者の上皮小体ホルモンを測定する手段および方法
JP2016523821A (ja) * 2013-04-24 2016-08-12 フラウンホーファーゲゼルシャフト ツール フォルデルング デル アンゲヴァンテン フォルシユング エー.フアー. アピコンプレクサ病原体に対する新規ワクチン
JP2021523702A (ja) * 2018-05-04 2021-09-09 オレゴン ヘルス アンド サイエンス ユニバーシティ ヒト抗aav2カプシドポリクローナル抗体エピトープ
JP2022549679A (ja) * 2019-09-27 2022-11-28 バイオマリン ファーマシューティカル インコーポレイテッド サイズ排除クロマトグラフィー及び多角度光散乱技術を使用した遺伝子療法ウイルス粒子のキャラクタリゼーション
WO2021191079A1 (en) 2020-03-24 2021-09-30 Puridify Ltd Characterization of gene therapy vectors
JP2023529417A (ja) * 2020-06-15 2023-07-10 サレプタ セラピューティクス, インコーポレイテッド アデノ関連ウイルス抗体及びそのフラグメント

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
CLACKSON ET AL., NATURE, vol. 352, no. 6336, 15 August 1991 (1991-08-15), pages 624 - 628
HASHIMOTO-GOTOH T. ET AL., GENE, vol. 152, 1995, pages 271 - 275
KOHLER G.MILSTEIN C., NATURE, vol. 256, no. 5517, 7 August 1975 (1975-08-07), pages 495 - 497
KRAMER W. ET AL., METHODS ENZYMOL., vol. 154, 1987, pages 350 - 367
KRAMER W. ET AL., NUCLEIC ACIDS RES., vol. 12, 1984, pages 9441 - 9456
KUNKEL TA., PROC NATL ACAD SCI USA., vol. 82, 1985, pages 488 - 492
MARKS ET AL., J MOL BIOL., vol. 222, no. 3, 5 December 1991 (1991-12-05), pages 581 - 597
MCKENZIE, T. ET AL., PLASMID, vol. 15, no. 2, 1986, pages 93 - 103
TATIANA A. TATSUSOVATHOMAS L. MADDEN, FEMS MICROBIOL. LETT., vol. 174, 1999, pages 247 - 250
YANGMIN GONG ET AL., JOURNAL OF BASIC MICROBIOLOGY, vol. 51, 2011, pages 666 - 672
YODOSHA: "Protein Experimental Handbook", 2003, pages: 92 - 96
ZOLLER MJ. ET AL., METHODS ENZYMOL., vol. 100, 1983, pages 468 - 500

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026048975A1 (ja) * 2024-08-29 2026-03-05 株式会社ダイセル Aavカプシドに結合する抗体

Also Published As

Publication number Publication date
CN122122177A (zh) 2026-05-29
JPWO2025100417A1 (cg-RX-API-DMAC7.html) 2025-05-15

Similar Documents

Publication Publication Date Title
CN103890174B (zh) IgG结合性肽及利用其检测和纯化IgG的方法
US20220088212A1 (en) C-terminal lysine conjugated immunoglobulins
JP2010515463A (ja) 配座的に束縛されたポリペプチド配列のコンビナトリアルライブラリー
US12492249B2 (en) Antibodies and use thereof
CN113993889A (zh) 与多个Fc同种型和亚类偶联的抗原结合片段
US20030017504A1 (en) Antibodies specific for poly(ethylene glycol)
CN113583112A (zh) Aav特异性抗体及其应用
CN105636976A (zh) 新型肽标签以及其用途
CN109863176B (zh) 与硫氧还蛋白1特异性结合的单克隆抗体及其用途
WO2018206738A1 (en) Light-switchable polypeptide and uses thereof
KR20210056398A (ko) 항 인간 심근 트로포닌 i의 항체 및 그 사용
JP2019030231A (ja) 抗体及びその製造方法、並びに抗体の熱安定性を向上させる方法
CN110885375B (zh) 特异性针对mmp-9蛋白锌离子结合结构域的单域抗体及产品与应用
CN116940684A (zh) 抗SARS-CoV-2抗体
CN104812773A (zh) 表位标记用抗体、杂交瘤细胞株以及其用途
WO2026048975A1 (ja) Aavカプシドに結合する抗体
JP2021523727A (ja) 大核酸の細胞内標的指向送達
CN106928360B (zh) 一种CD105纳米抗体Nb68
KR100914377B1 (ko) 스트랩토코쿠스 표면 항원 Ⅰ/Ⅱ와 특이적으로 결합하는diabody 및 이의 이용 방법
CN106928355A (zh) 一种CD105纳米抗体Nb184
US20040214242A1 (en) Method for the isolation of large variances of specific molecules for a target molecule from phagemid gene libraries, and a test kit
CN121405810B (zh) 一种靶向人和食蟹猴pd-l1交叉结合的单域抗体及其应用
JP6245688B2 (ja) IgY特異的結合ペプチド及びそれによるIgYの精製法
CN113173992B (zh) 一种白细胞抗原结合多肽
JP5733693B2 (ja) 組換え型ポリペプチドの製造方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24888712

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2025556404

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 202647067396

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 202647067396

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2024888712

Country of ref document: EP

Effective date: 20260608

WWE Wipo information: entry into national phase

Ref document number: 2024888712

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE